Your browser is no longer supported. Please, upgrade your browser.
Settings
REGN Regeneron Pharmaceuticals, Inc. daily Stock Chart
REGN [NASD]
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E48.38 EPS (ttm)7.71 Insider Own1.40% Shs Outstand106.08M Perf Week-1.92%
Market Cap39.57B Forward P/E24.04 EPS next Y15.52 Insider Trans-0.48% Shs Float78.08M Perf Month3.34%
Income895.50M PEG2.59 EPS next Q3.06 Inst Own69.70% Short Float2.81% Perf Quarter2.17%
Sales4.86B P/S8.14 EPS this Y39.50% Inst Trans-1.96% Short Ratio2.35 Perf Half Y-8.58%
Book/sh42.33 P/B8.81 EPS next Y19.80% ROA13.80% Target Price423.43 Perf Year0.59%
Cash/sh9.79 P/C38.09 EPS next 5Y18.68% ROE21.30% 52W Range325.35 - 452.96 Perf YTD1.61%
Dividend- P/FCF41.15 EPS past 5Y38.80% ROI18.20% 52W High-17.65% Beta1.35
Dividend %- Quick Ratio2.30 Sales past 5Y61.30% Gross Margin93.80% 52W Low14.65% ATR9.47
Employees5400 Current Ratio2.60 Sales Q/Q11.70% Oper. Margin27.40% RSI (14)48.79 Volatility2.38% 2.41%
OptionableYes Debt/Eq0.11 EPS Q/Q63.00% Profit Margin18.40% Rel Volume0.94 Prev Close365.02
ShortableYes LT Debt/Eq0.08 EarningsFeb 09 BMO Payout0.00% Avg Volume935.56K Price373.00
Recom2.20 SMA20-1.75% SMA501.12% SMA200-2.33% Volume880,540 Change2.19%
Mar-17-17Initiated Oppenheimer Perform
Mar-09-17Initiated UBS Buy $435
Feb-16-17Downgrade Goldman Buy → Neutral
Jan-06-17Reiterated RBC Capital Mkts Outperform $626 → $598
Jan-06-17Reiterated Chardan Capital Markets Neutral $350 → $345
Dec-20-16Upgrade Credit Suisse Neutral → Outperform
Dec-12-16Upgrade Chardan Capital Markets Sell → Neutral $300 → $350
Nov-07-16Reiterated Chardan Capital Markets Sell $325 → $300
Aug-05-16Downgrade Robert W. Baird Outperform → Neutral $505 → $448
Jun-29-16Initiated Bernstein Outperform
Apr-20-16Downgrade Wells Fargo Outperform → Market Perform
Mar-28-16Reiterated Canaccord Genuity Hold $525 → $450
Mar-17-16Reiterated Sun Trust Rbsn Humphrey Neutral $450 → $410
Mar-16-16Downgrade Chardan Capital Markets Neutral → Sell $375 → $325
Mar-15-16Initiated Gabelli & Co Buy $574
Mar-03-16Initiated Sun Trust Rbsn Humphrey Neutral $450
Feb-25-16Initiated Citigroup Buy $480
Feb-16-16Upgrade Chardan Capital Markets Sell → Neutral $400 → $375
Feb-10-16Reiterated RBC Capital Mkts Outperform $676 → $668
Feb-10-16Reiterated Leerink Partners Outperform $534 → $505
Mar-26-17 06:43AM  3 Top Biotech Stocks to Buy in 2017 at Motley Fool
Mar-24-17 08:15AM  Regeneron Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : REGN-US : March 24, 2017
07:47AM  Pharma Stock Roundup: Is Sanofi Buying Flexion? Pfizer, Merck KGaA Drug Approved
Mar-23-17 02:07PM  Regeneron, Sanofi Look To Crush Amgen, And Rivals Say They Can
Mar-22-17 08:01PM  [$$] DNA decoding initiative to involve 500,000 middle-aged Britons at Financial Times
08:01PM  GSK and Regeneron to mine gene data from 500,000 Britons
08:00PM  U.K. Biobank, Regeneron and GSK Announce Largest Gene Sequencing Initiative on World's Most Detailed Health Database to Improve Drug Discovery and Disease Diagnosis PR Newswire
Mar-21-17 02:45PM  Sanofi-Genzyme files preemptive legal strike to protect eczema drug at bizjournals.com
12:33PM  Sanofi, Regeneron sue Amgen to protect eczema drug from patent claims
Mar-20-17 04:09PM  Esperion And Medicines Co. Recover From Amgen-Induced Pitfall
10:26AM  Amgen (AMGN): Repatha Outcomes Data Disappoint, Shares Drop
04:24AM  European Stocks Drift Lower; Deutsche Bank Falls on Rights Issue Details
03:00AM  European Stocks Set For Mixed Open: Dollar Slumps in Quiet Asia Trade
Mar-17-17 11:47PM  Amgens Repatha Study Shows Reduced Risk of Heart Attack, Stroke at The Wall Street Journal
07:18PM  Amgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke at The Wall Street Journal
04:59PM  The Biggest Loser: Amgen Drops 6.4% at Barrons.com
04:50PM  Esperion's Dive On Amgen Heart Study 'Counterintuitive' On Pricing
01:18PM  Here's Why Amgen, The Medicines Company, and Esperion Therapeutics Are All Tanking Today at Motley Fool
01:03PM  CVS Health says Amgen data may increase eligible patients by millions
11:22AM  Express Scripts says Amgen data opens door to patients
10:38AM  Amgen Cholesterol Drug Cuts Risk of Heart Attack, Stroke but Not Enough to Quell Value Debate
09:37AM  Amgen Tanks On Heart Study; Shares Of Other Drugmakers Tumble
09:14AM  Cholesterol drug cuts heart risks, spurs new debate on cost
08:48AM  What are Sanofi's (SNY) Strengths and Challenges in 2017?
06:29AM  Coverage initiated on Regeneron Pharma by Oppenheimer
Mar-16-17 05:52PM  Billion dollar boost for Amgen?
10:16AM  Ocular's Dextenza Reports Positive Study Results at Investopedia
Mar-15-17 02:48PM  Sanofi, Regenerons Dupilumab Gets UK Early Access at Investopedia
Mar-14-17 09:29PM  Teen Scientist Researches New Approach to Neurological Damage; Wins Regeneron Science Talent Search 2017 PR Newswire
10:35AM  Amgen's Repatha Meets Primary Endpoint in Phase III Study
Mar-13-17 04:37PM  Amgen Tops Heart Study As Rivals Regeneron, Sanofi Chill In Court
09:24AM  Amgen's Repatha lowers need for cholesterol-lowering procedure
01:00AM  Data on heart benefits of Amgen drug is key to unlocking sales
Mar-11-17 09:06AM  3 Growth Stocks I'd Buy Right Now at Motley Fool
Mar-10-17 12:35PM  Vetr Downgrades Regeneron Off Of Share Rise
10:39AM  Regeneron Is Ready to Reanimate: Watch for a Breakout
10:39AM  Regeneron Could Generate More Upside
10:28AM  Why Amgen (AMGN) Stock Rallied After Q4 Earnings Release?
09:34AM  Regeneron Could Run Higher: Must-See Chart
09:25AM  Boston Scientific and Edwards Lifesciences Are in a Patent Battle
Mar-09-17 04:31PM  Momo Dives Despite Price Target Hike; UBS Initiates Biotechs; Mercury Is A Buy
01:57PM  Celgene's Deep Pipeline Can Reassure Investors
01:40PM  Drugs, travel, jewelry and social media in the blitz
01:14PM  Big winners & losers since Haines Bottom
12:38PM  3 Biotech Stocks to Buy Nowand 1 to Dump ASAP at Barrons.com
06:06AM  REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Fi
Mar-08-17 02:50PM  Intellia R&D head says new gene-editing data shows path to human trials at bizjournals.com
Mar-07-17 07:01PM  Cramer: When a Trump Tweet Is a Buy Signal
12:11PM  Drug innovators will continue to do well: Isaly
08:00AM  Regeneron and Sanofi to Present New Phase 3 Praluent® (alirocumab) Injection Clinical Trial Analyses at ACC.17 Scientific Sessions PR Newswire
07:04AM  Better Buy: Regeneron Pharmaceuticals, Inc. vs. Novartis at Motley Fool
Mar-06-17 07:39AM  5 FDA Decisions to Watch Out for in Mar 2017
Mar-04-17 07:25PM  Icahn's (Potential) Move Into Biotech
12:07PM  Sanofi, Regeneron say latest Dupixent eczema drug tests positive Reuters
10:32AM  Sanofi and Regeneron Announce Presentation of Positive Data from Long-Term Pivotal Phase 3 CHRONOS Study of Dupixent® (dupilumab) in Moderate-to-Severe Atopic Dermatitis GlobeNewswire
10:30AM  Regeneron and Sanofi Announce Presentation of Positive Data from Long-Term Pivotal Phase 3 CHRONOS Study of DUPIXENT® (dupilumab) in Moderate-to-Severe Atopic Dermatitis PR Newswire
Mar-02-17 09:06AM  Dupixent Could Demonstrate Efficacy across Multiple Indications in 2017
07:37AM  Dupixent May Help Diversify Regenerons Revenues in 2017
Mar-01-17 10:37AM  Regeneron Could See a Modest Rise in Net Profit Margins in 2017
09:07AM  Regeneron Expected to Witness Robust Growth in Revenues in 2017
07:38AM  Analyst Recommendations for Regeneron Pharmaceuticals in 2017
Feb-28-17 08:00AM  Kevzara (sarilumab) now available in Canada for the Treatment of Adult Patients with Moderately to Severely Active Rheumatoid Arthritis CNW Group
07:37AM  Understanding Alexions Profit Margin Trend in 2017
Feb-27-17 08:30AM  Sanofi and Regeneron to Present New Data on Dupixent® (dupilumab) for Moderate-to-Severe Atopic Dermatitis at Upcoming Medical Congresses PR Newswire
08:30AM  Regeneron and Sanofi to Present New Data on DUPIXENT® (dupilumab) for Moderate-to-Severe Atopic Dermatitis at Upcoming Medical Congresses PR Newswire
Feb-16-17 09:20AM  Why Amgen's Becoming One of My Top Dividend Stocks to Buy at Motley Fool
Feb-15-17 01:04PM  REGENERON PHARMACEUTICALS INC Financials
07:04AM  Biotech Stock Roundup: Regeneron's Praluent to Remain on Market for Now, GILD Presents HIV Data
Feb-14-17 05:12PM  ETFs with exposure to Regeneron Pharmaceuticals, Inc. : February 14, 2017
08:33AM  Regeneron Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : REGN-US : February 14, 2017
07:54AM  These 25 Companies Could Get a Big Profit Boost From a Little Known Part of Trump's Tax Reform
Feb-13-17 02:25PM  Regeneron: It's All Riding On Dupixent at Barrons.com
10:49AM  Regeneron Pharmaceuticals, Inc. :REGN-US: Earnings Analysis: 2016 By the Numbers : February 13, 2017
09:30AM  Regeneron Announces Upcoming 2017 Investor Conference Presentations PR Newswire
07:45AM  Early movers: AAPL, DD, TEVA, QSR, FDC, HAS, JCP & more at CNBC
Feb-10-17 02:50PM  3 Beaten-Down Stocks Ready to Bounce Back at Motley Fool
09:17AM  Regeneron Pharmaceuticals, Inc. :REGN-US: Earnings Analysis: Q4, 2016 By the Numbers : February 10, 2017
08:15AM  Blog Coverage Acorda's Stock Price Soared Above 20% on Positive Data from Parkinson Disease Late Stage Clinical Trial Accesswire
05:54AM  [$$] 12 Stocks to Benefit Most From the House Tax Plan at Barrons.com
Feb-09-17 06:00PM  Edited Transcript of REGN earnings conference call or presentation 9-Feb-17 1:30pm GMT
04:56PM  Regeneron Defies Light Q4 Sales, Eylea Outlook On Amgen-Rivaling LDL Win
04:26PM  Regeneron says it is being investigated by the US Attorney's Office over patient assistance nonprofit at MarketWatch
02:01PM  Regeneron: Whiplash! at Barrons.com
01:14PM  [$$] Regeneron Is Primed for a Second Act at The Wall Street Journal
01:11PM  Regeneron Pharmaceuticals Inc (REGN) and Sanofi SA (ADR) (SNY) Obtain Suspension of Injunction for Cholesterol Drug Sales at Insider Monkey
11:09AM  Regeneron (REGN) Misses on Q4 Earnings & Sales, View Bleak
10:56AM  Judge Lifts Ban on Amgen Cholesterol Drug Rival at Investopedia
10:03AM  Regeneron (REGN) Q4 Earnings Misses Estimates
09:05AM  Acorda, Amgen and Regeneron Lead Premarket Biotech Movers
08:33AM  Sanofi (SNY) Q4 Earnings In Line; Can Sell Praulent for Now
08:31AM  Regeneron forecasts 2017 U.S. Eylea sales growth below estimates
08:17AM  A Heart-Stopping Patent Injunction Stay For Sanofi at Forbes
07:51AM  Early movers: KO, TWTR, VIAB, CVS, YUM, RAI, & more at CNBC
07:17AM  REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
07:17AM  Regeneron misses Street 4Q forecasts
07:07AM  Q4 2016 Regeneron Pharmaceuticals Inc Earnings Release - Before Market Open
06:37AM  Regeneron revenue rises 11.7 pct on Eylea eye drug
06:30AM  Regeneron Reports Fourth Quarter and Full Year 2016 Financial and Operating Results PR Newswire
Feb-08-17 07:02PM  [$$] Appeals Court Allows Sanofi, Regeneron to Continue Selling Cholesterol Drug at The Wall Street Journal
05:46PM  Sanofi: Appeals Court Grants Stay of Permanent Injunction for Praluent® (alirocumab) During Appeals Process GlobeNewswire
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its products include EYLEA injection for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and ARCALYST injection for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children's. It also markets Kevzara injection for the treatment of rheumatoid arthritis in adults; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. The company also develops EYLEA, trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma. Regeneron Pharmaceuticals, Inc. has collaboration agreement with Sanofi for the development of antibody-based clinical products comprising Praluent, Sarilumab, Dupixent, REGN2810, REGN3500, and REGN3767; Bayer HealthCare LLC for the development of Nesvacumab/aflibercept, which is used in ophthalmology; and with Teva and Mitsubishi Tanabe Pharma Corporation for developing Fasinumab, an antibody to nerve growth factor, as well as collaboration agreement with Intellia Therapeutics, Inc., to advance CRISPR/Cas gene-editing technology for in vivo therapeutic development. The company was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
YANCOPOULOS GEORGEPresident Regeneron LaboratoriDec 15Option Exercise20.32195,0793,964,005697,000Dec 19 04:09 PM
SCHLEIFER LEONARD SPresident & CEODec 15Option Exercise20.32250,0005,080,000292,806Dec 19 04:07 PM
BAKER CHARLES ADirectorDec 12Option Exercise18.613,00055,83012,000Dec 14 05:41 PM
BAKER CHARLES ADirectorDec 12Sale392.023,0001,176,0489,000Dec 14 05:41 PM
RYAN ARTHUR FDirectorNov 15Sale429.342,000858,68036,500Nov 16 04:21 PM
GOLDSTEIN JOSEPH LDirectorNov 14Option Exercise273.672,125581,54915,125Nov 15 04:08 PM
GOLDSTEIN JOSEPH LDirectorNov 14Sale450.002,125956,25013,000Nov 15 04:08 PM
VAGELOS P ROYChairman of the BoardNov 07Option Exercise20.3276,8951,562,506515,726Nov 09 04:10 PM
GOLDSTEIN JOSEPH LDirectorJul 29Option Exercise273.672,125581,54915,125Aug 01 04:04 PM
GOLDSTEIN JOSEPH LDirectorJul 29Sale425.002,125903,12513,000Aug 01 04:04 PM
RYAN ARTHUR FDirectorMay 24Sale396.641,000396,64039,500May 25 04:02 PM
Van Plew Daniel PEVP & General Mgr Industrial OMay 18Sale385.774,4131,702,4031,921May 19 04:26 PM
Van Plew Daniel PEVP & General Mgr Industrial OMay 17Option Exercise30.639,460289,76011,381May 19 04:26 PM
VAGELOS P ROYChairman of the BoardMay 12Option Exercise20.32230,6844,687,499563,564May 13 04:40 PM
GOLDSTEIN JOSEPH LDirectorApr 06Option Exercise177.821,000177,82014,000Apr 07 04:19 PM
GOLDSTEIN JOSEPH LDirectorApr 06Sale425.002,000850,00013,000Apr 07 04:19 PM
GOLDSTEIN JOSEPH LDirectorApr 01Option Exercise177.822,000355,64016,000Apr 04 04:16 PM
GOLDSTEIN JOSEPH LDirectorApr 01Sale400.002,000800,00014,000Apr 04 04:16 PM